<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, Anne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Waldo, Albert L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Drug Therapy for AF: Current Options and Future Promise</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">32-34</style></pages><abstract><style  face="normal" font="default" size="100%">In atrial fibrillation (AF), rhythm control involves a strategy that is designed to restore and maintain sinus rhythm by preventing recurrences, initially by cardioversion (pharmacological or electrical). Rate control focuses on strategies to slow the ventricular response in patients with AF. With either strategy, anticoagulation is also recommended in patients who are at moderate to high risk of stroke.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>